Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalisations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5 and XBB transmission
Liang En Wee, An Ting Tay, Calvin Chiew, Barnaby Edward Young, Betty Wong, Ruth Lim, Ching Li Lee, Joyce Tan, Shawn Vasoo, David Chien Lye, Kelvin Bryan Tan
Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.06.016
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalisations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5 and XBB transmission
Declarations
Declaration of interests The authors report no conflicts of interest.
Contribution statement LEW contributed to literature search and writing of the manuscript. ATT, CC, BEY, BW, RL, CLL, JT, SV, DCL and KBT contributed to critical review and editing of the manuscript. DCL and KBT provided supervision. KBT, ATT contributed to study design, data collection, and data analysis. All authors had full access to all the data in the study and take responsibility for the decision to submit for publication. KBT and ATT directly accessed and verified the underlying data reported in the manuscript. J o u r n a l P r e -p r o o f
References
Aggarwal, Molina, Beaty, Bennett, Carlson et al., Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study, Lancet Infect Dis,
doi:10.1016/S1473-3099(23)00056-7Arbel, Sagy, Hoshen, Battat, Lavie et al., Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge, N Engl J Med,
doi:10.1056/NEJMoa2204919Bajema, Wang, Hynes, Rowneki, Hickok et al., Early Adoption of Anti-SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2022.41434Britton, Embi, Levy, Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance -VISION Network, 10 States, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm7142a4Dryden-Peterson, Kim, Kim, Caniglia, Lennes et al., Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study, Ann Intern Med,
doi:10.7326/M22-2141Genomics, Hope, Charlett, Chand, Ghani et al., Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study, Lancet,
doi:10.1016/S0140-6736(22)00462-7Gold, Kelleher, Magid, Jackson, Pennini et al., Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability -United States, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm7125e1Guenter, Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely, Clin Microbiol Infect,
doi:10.1016/j.cmi.2022.11.028Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle et al., EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Imai, Ito, Kiso, Yamayoshi, Uraki et al., Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB, N Engl J Med,
doi:10.1056/NEJMc2214302Li, Thomas, Li, Addressing Extreme Propensity Scores via the Overlap Weights, Am J Epidemiol,
doi:10.1093/aje/kwy201Nyberg, Ferguson, Nash, Webster, Flaxman et al., None
Pfizer, additional-data-paxlovidtm-supporting Pfizer reports additional data on PAXLOVID supporting upcoming new drug application submission to U
Sackett, Deeks, Altman, Down with odds ratios! Evidence Based Medicine
Savinkina, Paltiel, Ross, Gonsalves, Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing-A Cost-effectiveness Analysis. Open Forum Infect Dis,
doi:10.1093/ofid/ofac637Schwartz, Wang, Tadrous, Langford, Daneman et al., Population-based evaluation of the effectiveness of nirmatrelvirritonavir for reducing hospital admissions and mortality from COVID-19, CMAJ,
doi:10.1503/cmaj.221608Tan, Chiew, Lee, Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore, Ann Intern Med,
doi:10.7326/M22-2042Tan, Chiew, Pang, Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study, Clin Microbiol Infect,
doi:10.1016/j.cmi.2022.08.002Wagstaff, Health systems in East Asia: what can developing countries learn from Japan and the Asian Tigers? Health Econ,
doi:10.1002/hec.1180Wai, Chan, Cheung, Wang, Chan et al., Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg Health West Pac,
doi:10.1016/j.lanwpc.2022.100602Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet,
doi:10.1016/S0140-6736(22)01586-0Xie, Bowe, Al-Aly, Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records, BMJ,
doi:10.1136/bmj-2022-073312Yip, Lui, Lai, Wong, Tse et al., Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients, Clin Infect Dis,
doi:10.1093/cid/ciac687{ 'indexed': {'date-parts': [[2023, 6, 17]], 'date-time': '2023-06-17T04:25:25Z', 'timestamp': 1686975925667},
'reference-count': 29,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2023, 6, 1]],
'date-time': '2023-06-01T00:00:00Z',
'timestamp': 1685577600000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}],
'content-domain': { 'domain': ['clinicalmicrobiologyandinfection.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2023, 6]]},
'DOI': '10.1016/j.cmi.2023.06.016',
'type': 'journal-article',
'created': {'date-parts': [[2023, 6, 17]], 'date-time': '2023-06-17T01:42:07Z', 'timestamp': 1686966127000},
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalisations and severe '
'COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5 and XBB '
'transmission',
'prefix': '10.1016',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6428-9999',
'authenticated-orcid': False,
'given': 'Liang En',
'family': 'Wee',
'sequence': 'first',
'affiliation': []},
{'given': 'An Ting', 'family': 'Tay', 'sequence': 'additional', 'affiliation': []},
{'given': 'Calvin', 'family': 'Chiew', 'sequence': 'additional', 'affiliation': []},
{'given': 'Barnaby Edward', 'family': 'Young', 'sequence': 'additional', 'affiliation': []},
{'given': 'Betty', 'family': 'Wong', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ruth', 'family': 'Lim', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ching Li', 'family': 'Lee', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joyce', 'family': 'Tan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Shawn', 'family': 'Vasoo', 'sequence': 'additional', 'affiliation': []},
{'given': 'David Chien', 'family': 'Lye', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kelvin Bryan', 'family': 'Tan', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'issue': '15',
'key': '10.1016/j.cmi.2023.06.016_bib1',
'doi-asserted-by': 'crossref',
'first-page': '1397',
'DOI': '10.1056/NEJMoa2118542',
'article-title': 'Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19',
'volume': '386',
'author': 'Hammond',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'issue': '10332',
'key': '10.1016/j.cmi.2023.06.016_bib2',
'doi-asserted-by': 'crossref',
'first-page': '1303',
'DOI': '10.1016/S0140-6736(22)00462-7',
'article-title': 'Comparative analysis of the risks of hospitalisation and death '
'associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) '
'variants in England: a cohort study',
'volume': '399',
'author': 'Nyberg',
'year': '2022',
'journal-title': 'Lancet'},
{ 'issue': '9',
'key': '10.1016/j.cmi.2023.06.016_bib3',
'doi-asserted-by': 'crossref',
'first-page': '790',
'DOI': '10.1056/NEJMoa2204919',
'article-title': 'Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge',
'volume': '387',
'author': 'Arbel',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'issue': '1',
'key': '10.1016/j.cmi.2023.06.016_bib4',
'doi-asserted-by': 'crossref',
'first-page': '77',
'DOI': '10.7326/M22-2141',
'article-title': 'Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health '
'System : A Population-Based Cohort Study',
'volume': '176',
'author': 'Dryden-Peterson',
'year': '2023',
'journal-title': 'Ann Intern Med'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib5',
'doi-asserted-by': 'crossref',
'article-title': 'Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 '
'during the era of omicron variants including BA.4 and BA.5 in Colorado, '
'USA: a retrospective cohort study',
'author': 'Aggarwal',
'year': '2023',
'journal-title': 'Lancet Infect Dis',
'DOI': '10.1016/S1473-3099(23)00011-7'},
{ 'issue': '10359',
'key': '10.1016/j.cmi.2023.06.016_bib6',
'doi-asserted-by': 'crossref',
'first-page': '1213',
'DOI': '10.1016/S0140-6736(22)01586-0',
'volume': '400',
'author': 'Wong',
'year': '2022',
'journal-title': 'Lancet'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib7',
'first-page': 'ciac687',
'article-title': 'Impact of the use of oral antiviral agents on the risk of '
'hospitalization in community COVID-19 patients',
'author': 'Yip',
'year': '2022',
'journal-title': 'Clin Infect Dis'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib8',
'article-title': 'Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable '
'mortality, hospital admissions and related avoidable healthcare system '
'cost among high-risk patients with mild to moderate COVID-19',
'volume': '30',
'author': 'Wai',
'year': '2023',
'journal-title': 'Lancet Reg Health West Pac'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib9',
'unstructured': 'Pfizer, New York, USA. '
'https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting '
'Pfizer reports additional data on PAXLOVID supporting upcoming new drug '
'application submission to U.S. FDA [press release]. 2022 [cited 2023 Jan '
'24].'},
{ 'issue': '13',
'key': '10.1016/j.cmi.2023.06.016_bib10',
'doi-asserted-by': 'crossref',
'first-page': 'E220',
'DOI': '10.1503/cmaj.221608',
'article-title': 'Population-based evaluation of the effectiveness of '
'nirmatrelvir–ritonavir for reducing hospital admissions and mortality '
'from COVID-19',
'volume': '195',
'author': 'Schwartz',
'year': '2023',
'journal-title': 'CMAJ'},
{ 'issue': '11',
'key': '10.1016/j.cmi.2023.06.016_bib11',
'article-title': 'Nirmatrelvir and risk of hospital admission or death in adults with '
'covid-19: emulation of a randomized target trial using electronic '
'health records',
'volume': '381',
'author': 'Xie',
'year': '2023',
'journal-title': 'BMJ'},
{ 'issue': '1',
'key': '10.1016/j.cmi.2023.06.016_bib12',
'doi-asserted-by': 'crossref',
'first-page': '89',
'DOI': '10.1056/NEJMc2214302',
'article-title': 'Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB',
'volume': '388',
'author': 'Imai',
'year': '2023',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib13',
'unstructured': 'Ministry of Health, Singapore '
'https://www.covid.gov.sg/well-and-positive-or-condition-assessed-mild-by-doctor/ '
'COVID-19 protocols [Internet]. 2022 [cited 2023 Jan 24]'},
{ 'issue': '22',
'key': '10.1016/j.cmi.2023.06.016_bib14',
'first-page': '00418',
'article-title': 'Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly '
'vaccinated Asian setting: a test-negative design study',
'volume': '24',
'author': 'Tan',
'year': '2022',
'journal-title': 'Clin Microbiol Infect'},
{ 'issue': '11',
'key': '10.1016/j.cmi.2023.06.016_bib15',
'doi-asserted-by': 'crossref',
'first-page': '1622',
'DOI': '10.7326/M22-2042',
'article-title': 'Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron '
'Variant Among Elderly People in Singapore',
'volume': '175',
'author': 'Tan',
'year': '2022',
'journal-title': 'Ann Intern Med'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib16',
'unstructured': 'Ministry of Health, Singapore '
'https://www.moh.gov.sg/news-highlights/details/update-on-covid-19-situation-and-measures-to-protect-healthcare-capacity. '
'Update on COVID-19 situation- XBB subvariant [Internet]. 2022 [cited '
'2023 Jan 24]'},
{ 'issue': '10305',
'key': '10.1016/j.cmi.2023.06.016_bib17',
'doi-asserted-by': 'crossref',
'first-page': '1091',
'DOI': '10.1016/S0140-6736(21)00252-X',
'article-title': "Singapore's health-care system: key features, challenges, and shifts",
'volume': '398',
'author': 'Tan',
'year': '2021',
'journal-title': 'Lancet'},
{ 'issue': '42',
'key': '10.1016/j.cmi.2023.06.016_bib18',
'doi-asserted-by': 'crossref',
'first-page': '1335',
'DOI': '10.15585/mmwr.mm7142a4',
'article-title': 'Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated '
'Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 '
'Omicron Predominance - VISION Network, 10 States, December',
'volume': '71',
'author': 'Britton',
'year': '2022',
'journal-title': 'MMWR Morb Mortal Wkly Rep'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib19',
'unstructured': 'Ministry of Health, Singapore '
'https://www.moh.gov.sg/covid-19/vaccination/statistics Vaccination '
'statistics [Internet]. 2022 [cited 2023 Jan 24]'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib20',
'unstructured': 'National Centre for Infectious Diseases, Singapore. Updated COVID-19 '
'Therapy Guidance and Oral Antiviral Prescribing Checklist. [Internet]. '
'2022 [cited 2023 Jan 24]'},
{ 'issue': '5',
'key': '10.1016/j.cmi.2023.06.016_bib21',
'doi-asserted-by': 'crossref',
'first-page': '441',
'DOI': '10.1002/hec.1180',
'article-title': 'Health systems in East Asia: what can developing countries learn from '
'Japan and the Asian Tigers?',
'volume': '16',
'author': 'Wagstaff',
'year': '2007',
'journal-title': 'Health Econ'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib22',
'unstructured': 'Centre for Evidence Based Medicine, Oxford, United Kingdom. Number '
'needed to treat (NNT). [cited 2023 8th April]; Available from: '
'http://www.cebm.net/number-needed-to-treat-nnt/. 2023.'},
{ 'issue': '6',
'key': '10.1016/j.cmi.2023.06.016_bib23',
'first-page': '164',
'article-title': 'Down with odds ratios',
'volume': '1',
'author': 'Sackett',
'year': '1996',
'journal-title': 'Evidence Based Medicine'},
{ 'issue': '1',
'key': '10.1016/j.cmi.2023.06.016_bib24',
'first-page': '250',
'article-title': 'Addressing Extreme Propensity Scores via the Overlap Weights',
'volume': '188',
'author': 'Li',
'year': '2019',
'journal-title': 'Am J Epidemiol'},
{ 'issue': '22',
'key': '10.1016/j.cmi.2023.06.016_bib25',
'first-page': '00601',
'article-title': 'Who should receive oral antiviral therapy for severe acute respiratory '
'syndrome coronavirus 2 infection in the omicron era? Choose wisely',
'volume': '7',
'author': 'Guenter',
'year': '2022',
'journal-title': 'Clin Microbiol Infect'},
{ 'issue': '12',
'key': '10.1016/j.cmi.2023.06.016_bib26',
'doi-asserted-by': 'crossref',
'first-page': 'ofac637',
'DOI': '10.1093/ofid/ofac637',
'article-title': 'Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing-A '
'Cost-effectiveness Analysis',
'volume': '9',
'author': 'Savinkina',
'year': '2022',
'journal-title': 'Open Forum Infect Dis'},
{ 'key': '10.1016/j.cmi.2023.06.016_bib27',
'unstructured': 'Ministry of Health, Singapore. '
'https://www.moh.gov.sg/news-highlights/details/increased-accessibility-to-paxlovid-for-eligible-covid-19-patients '
'Increased accessibility to paxlovid for eligible COVID-19 patients. '
'[Internet]. 2022 [cited 2023 Jan 24]'},
{ 'issue': '25',
'key': '10.1016/j.cmi.2023.06.016_bib28',
'doi-asserted-by': 'crossref',
'first-page': '825',
'DOI': '10.15585/mmwr.mm7125e1',
'article-title': 'Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip '
'Code-Level Social Vulnerability - United States, December 23, 2021-May '
'21, 2022',
'volume': '71',
'author': 'Gold',
'year': '2022',
'journal-title': 'MMWR Morb Mortal Wkly Rep'},
{ 'issue': '11',
'key': '10.1016/j.cmi.2023.06.016_bib29',
'doi-asserted-by': 'crossref',
'DOI': '10.1001/jamanetworkopen.2022.41434',
'article-title': 'Early Adoption of Anti-SARS-CoV-2 Pharmacotherapies Among US Veterans '
'With Mild to Moderate COVID-19, January and February 2022',
'volume': '5',
'author': 'Bajema',
'year': '2022',
'journal-title': 'JAMA Netw Open'}],
'container-title': 'Clinical Microbiology and Infection',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1198743X2300294X?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S1198743X2300294X?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2023, 6, 17]],
'date-time': '2023-06-17T01:42:26Z',
'timestamp': 1686966146000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1198743X2300294X'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 6]]},
'references-count': 29,
'alternative-id': ['S1198743X2300294X'],
'URL': 'http://dx.doi.org/10.1016/j.cmi.2023.06.016',
'relation': {},
'ISSN': ['1198-743X'],
'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'],
'container-title-short': 'Clinical Microbiology and Infection',
'published': {'date-parts': [[2023, 6]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 '
'hospitalisations and severe COVID-19 in community-dwelling elderly Singaporeans '
'during Omicron BA.2, BA.4/5 and XBB transmission',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'Clinical Microbiology and Infection',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.cmi.2023.06.016',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2023 European Society of Clinical Microbiology and Infectious Diseases. '
'Published by Elsevier Ltd. All rights reserved.',
'name': 'copyright',
'label': 'Copyright'}]}
